Your browser doesn't support javascript.
A SARS-CoV-2 cytopathicity dataset generated by high-content screening of a large drug repurposing collection.
Ellinger, Bernhard; Bojkova, Denisa; Zaliani, Andrea; Cinatl, Jindrich; Claussen, Carsten; Westhaus, Sandra; Keminer, Oliver; Reinshagen, Jeanette; Kuzikov, Maria; Wolf, Markus; Geisslinger, Gerd; Gribbon, Philip; Ciesek, Sandra.
  • Ellinger B; Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Hamburg, 22525, Germany. corona.repurposing@ime.fraunhofer.de.
  • Bojkova D; University Hospital Frankfurt, 60590, Frankfurt am Main, Germany.
  • Zaliani A; Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Hamburg, 22525, Germany.
  • Cinatl J; University Hospital Frankfurt, 60590, Frankfurt am Main, Germany.
  • Claussen C; Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Hamburg, 22525, Germany.
  • Westhaus S; Fraunhofer Cluster of Excellence for Immune Mediated Diseases CIMD, Frankfurt am Main, 60596, Germany.
  • Keminer O; University Hospital Frankfurt, 60590, Frankfurt am Main, Germany.
  • Reinshagen J; Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Hamburg, 22525, Germany.
  • Kuzikov M; Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Hamburg, 22525, Germany.
  • Wolf M; Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Hamburg, 22525, Germany.
  • Geisslinger G; Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Hamburg, 22525, Germany.
  • Gribbon P; Pharmazentrum Frankfurt/ZAFES, Institut für Klinische Pharmakologie, Klinikum der Goethe-Universität Frankfurt, 60590, Frankfurt am Main, Germany.
  • Ciesek S; Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, 60596, Frankfurt am Main, Germany.
Sci Data ; 8(1): 70, 2021 02 26.
Article in English | MEDLINE | ID: covidwho-1104525
ABSTRACT
SARS-CoV-2 is a novel coronavirus responsible for the COVID-19 pandemic, in which acute respiratory infections are associated with high socio-economic burden. We applied high-content screening to a well-defined collection of 5632 compounds including 3488 that have undergone previous clinical investigations across 600 indications. The compounds were screened by microscopy for their ability to inhibit SARS-CoV-2 cytopathicity in the human epithelial colorectal adenocarcinoma cell line, Caco-2. The primary screen identified 258 hits that inhibited cytopathicity by more than 75%, most of which were not previously known to be active against SARS-CoV-2 in vitro. These compounds were tested in an eight-point dose response screen using the same image-based cytopathicity readout. For the 67 most active molecules, cytotoxicity data were generated to confirm activity against SARS-CoV-2. We verified the ability of known inhibitors camostat, nafamostat, lopinavir, mefloquine, papaverine and cetylpyridinium to reduce the cytopathic effects of SARS-CoV-2, providing confidence in the validity of the assay. The high-content screening data are suitable for reanalysis across numerous drug classes and indications and may yield additional insights into SARS-CoV-2 mechanisms and potential therapeutic strategies.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Drug Repositioning / SARS-CoV-2 Type of study: Prognostic study Topics: Traditional medicine Limits: Humans Language: English Journal: Sci Data Year: 2021 Document Type: Article Affiliation country: S41597-021-00848-4

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Drug Repositioning / SARS-CoV-2 Type of study: Prognostic study Topics: Traditional medicine Limits: Humans Language: English Journal: Sci Data Year: 2021 Document Type: Article Affiliation country: S41597-021-00848-4